AIM ImmunoTech, Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The Company’s lead product, Ampligen® (rintatolimod), is an immuno-modulator with broad spectrum activity being developed for myriad indications.
NYSEAMERICAN: AIM
IR Website: aimimmuno.com
Headquarters: Ocala, FL
TALK TO MANAGEMENT
AIM ImmunoTech Inc. is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Summary
AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers as well as immune-deficiency disorders and viral diseases including COVID-19. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the antiviral defense system of the human body, as well as to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.
AIM ImmunoTech’s flagship products include Ampligen® (rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon alfa-n3). Ampligen® represents an RNA being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen® is approved in Argentina for the treatment of severe chronic fatigue syndrome (CFS) and is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Post COVID-Conditions. Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina. Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory (resistant to other treatment) or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older.
Press Releases
Investor Presentation
To download the AIM ImmunoTech Inc. investor presentation, please fill out the form below.
Stock Chart (Intraday)
Stock Chart (Historical)
Ampligen® - A Wide Variety of Potential Applications
-
Generally well-tolerated with over 100,000 IV doses in humans
-
Clinically tested in oncology as a single-agent therapeutic and in combination with other agents
-
Potential in oncology to enhance efficacy of PD-1 and PD-L1 checkpoint inhibitors1
-
Phase 3 in ME/CFS completed in U.S. – NDA filing pending confirmatory Phase 3 following complete response letter; Approved for the treatment of severe CFS in Argentina
1: Animal experiments support expectations of human responses

Additionally, Ampligen® induces a wide range of immunologic and anti-tumor activities, making it a potentially useful immuno-therapy targeting multiple cancers with high unmet needs.
Site: Erasmus University, The Netherlands, conducted by Professor CHJ van Eijck, MD, PhD
Eligibility: Adults with metastatic or locally advanced pancreatic carcinoma following FOLFIRINOX
Survival Data: Median overall survival (OS) was 19 months in the Ampligen® cohort compared to 12 months for a well-matched historical control group (p=0.035) 19 months OS in Ampligen® cohort represents 7.9 month increase survival benefit compared to current standard of care (FOLFIRINOX followed by gemcitabine), which yields 11.1 months OS
Received IND clearance from the U.S. FDA and IRB approval to initiate Phase 2 study in locally advanced pancreatic cancer patients
Lastly, Ampligen® may mount a potentially broad spectrum immune system response against SARS-CoV-2 (COVID-19)
Next Steps: Planning intranasal study of Ampligen® to potentially enhance and expand natural immunity

Alferon N Injection®
The Alferon N Injection® is currently an approved treatment of refractory or recurrent external condylomata acuminata. Commercial launch is pending FDA manufacturing approval, and sales are anticipated to resume upon successful pre-approval inspection and supplemental approval by FDA.
Strategic Partnerships
AIM ImmunoTech has developed strategic partnerships with groups such as the University of Pittsburgh Medical Center as well as the Roswell Park Comprehensive Cancer Center for their oncology treatment trials.
Market Potential
AIM ImmunoTech believes that it has potential solutions for a number of different indications, both for use in isolation as well as in conjunction with another drug.
First, Ampligen is in late stage trials for treatment for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Up to 2.5 million Americans are estimated to suffer from this malady, causing the U.S. economy an estimated $17 to $24 billion per year according to the CDC.
Additionally, Ampligen is currently being studied for alleviation of "long COVID"; the long-term issues some COVID patients suffer from. While there is not much long term information to draw from, a recent UCLA study implies that around 30% of COVID patients have long-term symptoms.
Lastly, oncology: AIM ImmunoTech believes that it may have therapeutic solutions for numerous types of cancer. As a malady that impacts so many of us, obviously the potential market for these therapeutics is enormous. Precedence Research estimates that the global market will balloon to over $580 billion annually in 2030, with a Compounded Annual Growth Rate (CAGR) of 8.2% this decade.
Current Pipeline
Strong Cash Position & Poised for Commercialization
For biotech companies, having enough runway to develop their candidates and get through the regulatory process takes an incredible amount of cash and time. Many are not able to see their candidates through because of a shortage of cash.
AIM ImmunoTech is currently in a very advantageous position in this regard. Its cash and cash equivalents position as of the end of Q2 2022 sat at about $35 million, offering it a lengthy runway to achieve its goals and reach commercialization.

While a strong cash position is no guarantee that its candidates will successfully move through the regulatory approval process, its cash position combined with a strong intellectual property stack puts it in a strong position for future success.
NOTE: since the creation of the above graphic, AIM ImmunoTech has also earned the FDA Orphan Drug Designation
Video: Virtual Investor Spotlight Series
AIM ImmunoTech Virtual Investor Video: Aug 3, 2022
SEC Filings
Management Overview

Thomas K. Equels, M.S. J.D.
Chief Executive Officer
THOMAS K. EQUELS, M.S., J.D., was named Chief Executive Officer in February 2016, served as President since August 2015, has been a Director since 2008 and presently serves as AIM ImmunoTech’s Executive Vice Chairman.

Peter W. Rodino III, JD
Chief Operating Officer, Executive Director for Governmental Relations, General Counsel, Secretary
PETER W. RODINO, III, Esq., was named Executive Director for Governmental Relations and General Counsel in October 2016 and Secretary of the Company in November 2016.

Robert Dickey IV
Chief Financial Officer
ROBERT DICKEY IV has more than 25 years of experience of C-suite financial leadership for life science and medical device companies, both private and public, ranging from preclinical development to commercial operations and across a variety of disease areas and medical technologies
Risks & Disclosures
This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
AIM ImmunoTech Inc. (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
b2i digital or its related entities may own securities of the Company.
The Company is a client of b2i Digital. The Company agreed to pay b2i Digital no greater than $100,000 in cash for 12 months of digital marketing consulting and investor awareness services.
This communication includes forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks, uncertainties and other factors. The Company urges readers to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this communion. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this communication.
The AIM ImmunoTech's management and investor relations team is available to talk to current and potential investors. They're happy to answer your questions and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
• Directly hear the AIM ImmunoTech story
• Ask your questions
• Submit the form below and someone will get in touch with you as soon as possible
Note: Company management or its representative can only discuss and disclose information that is already available in the public domain. They will do their best to clarify such information to the extent permitted by securities law and industry regulations.